FILING ANALYSIS · TUESDAY, NOVEMBER 3
CORCEPT THERAPEUTICS INC CORT — 8-K: Results of Operations and Financial Condition
positive
Corcept Therapeutics reported a 64% increase in revenue to $340.5 million, with net income of $126.8 million, and reiterated its 2026 revenue guidance of $1.1-$1.2 billion. The company also announced positive results from its BELLA Part A trial, demonstrating clinically meaningful progression-free survival and overall survival in patients with platinum-resistant ovarian cancer.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →